Skip to content
S7413Senate2023-2024 SessionSame asA2163

Protect Patients’ Medication Safety

Official title

“Establishes patient safety and quality assurance measures regarding the distribution of patient-specific medication from an insurer-designated pharmacy”

Sponsor Neil D. BreslinSD-46Affects Finance
Status
In Senate Committee
Insurance
Impact
7/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

This bill establishes patient safety and quality assurance standards for insurer-designated pharmacies distributing patient-specific medications to healthcare providers for administration.

Why it matters

  1. Reduces risk of patient error and mishandling. By prohibiting insurers from requiring patients to transport specialty medications themselves to clinics for administration, the bill protects patients from potential safety hazards such as improper storage, temperature excursions, or loss.

  2. Imposes strict safety and quality requirements on insurer-designated pharmacies. The legislation mandates cold chain logistics, accreditation, same-day delivery, and 24/7 clinical access, which together raise the bar for how medications are handled and delivered to healthcare providers.

  3. Supports provider flexibility and patient safety with exceptions. The bill requires expedited exceptions for cases where it is unsafe for a patient to use an insurer-designated pharmacy, and bans insurer-mandated distribution for medications that require sterile compounding or same-day, patient-specific dosing, protecting complex and time-sensitive therapies.

  4. Addresses provider payment and administrative burdens. By mandating “site neutral” payment that covers providers’ costs for intake, storage, and disposal, the bill aims to prevent financial disincentives for clinics and hospitals to accept insurer-designated medications, ensuring patient access and provider cooperation.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Health insurers and health care plans

    The bill would require agreements with treating providers before mandating delivery of patient-specific medications from designated pharmacies and prohibit those mandates for drugs requiring provider sterile compounding or dosing based on same-day test results.

  • Physicians, hospitals and clinics

    Required agreements would include site-neutral payment covering medication intake, storage and disposal costs, plus expedited exceptions when providers certify that designated-pharmacy supply is unsafe for a patient.

  • Insurer-designated pharmacies

    Required agreements would include same-day delivery, round-the-clock pharmacist or nurse access, temperature controls, supply-chain documentation and national accreditation.

  • Patients receiving provider-administered medications

    The bill would prohibit plans from allowing or requiring designated pharmacies to dispense drugs for patients to transport to providers and from requiring home infusion or an infusion site outside the patient's provider office or clinic.

Headline styles

Protect Patients’ Medication Safety

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Neil D. Breslin

Senator · Senate District 46

Chair, Ethics And Internal GovernanceChair, Insurance

No co-sponsors yet.

History

  1. Referred to insurance
  2. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A2163Assembly

Protect Patients' Medication Safety

In Assembly Committee · Insurance · Sponsor Linda Rosenthal

Impact 7 · Significant0% to pass

Full text

4 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

7413

2023-2024 Regular Sessions

IN SENATE

May 23, 2023

Introduced by Sen. BRESLIN -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance

AN ACT to amend the insurance law and the public health law, in relation to establishing patient safety and quality assurance measures regarding the distribution of patient-specific medication from an insurerdesignated pharmacy

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Section 3217-b of the insurance law is amended by adding a new subsection (p) to read as follows:

(p) (1) No insurer subject to this article shall by contract, written policy or written procedure allow or require an insurer-designated pharmacy to dispense a medication directly to a patient with the intention that such patient will transport such medication to a physician's office, hospital or clinic for administration.

(2) An insurer subject to this article may offer coverage for, but shall not require the use of a home infusion pharmacy to dispense sterile intravenous drugs ordered by physicians to patients in their homes or the use of an infusion site external to a patient's provider office or clinic.

(3) An insurer subject to this article, in order to require the distribution of patient-specific medication from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration, shall establish an agreement with the physician, hospital or clinic responsible for receiving and administering such medications to ensure proper receipt, transfer, handling, and storage of the medication prior to administration that includes, but is not limited to, the following provisions:

(A) provide at least ninety days' notice to providers and insurers prior to the implementation of such a requirement;

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD05796-01-3

(B) have a patient-specific expedited exception process for cases in which a provider certifies that it is unsafe for a patient to receive medication from an insurer-designated pharmacy;

(C) provide same day delivery of medications;

(D) make available on-call access to a pharmacist or nurse twenty-four hours per day, seven days per week;

(E) utilize cold chain logistics or other means to ensure a drug remains at the appropriate temperature through all stages of supply and storage;

(F) provide a medication's pedigree to certify to the physician's office, hospital or clinic that the drug was handled appropriately through the supply chain;

(G) demonstrate expertise and reliability in risk evaluation and mitigation strategy to comply with United States food and drug administration reporting requirements;

(H) demonstrate the insurer-designated pharmacy is accredited by a national accreditation organization;

(I) demonstrate ability to deliver medications to a physician's office, hospital or clinic in a clinically appropriate dosage and in a ready-to-administer dosage form; and

(J) offer site neutral payment for such medications to the physician's office, hospital or clinic administering the medication, which payment shall include the costs for the providers to intake, store and dispose of such medications.

(4) No insurer subject to this article shall by contract, written policy or written procedure require (A) a medication requiring sterile compounding by the provider, or (B) a medication with a patient-specific dosage requirement to be based upon lab or test results on the day of the patient visit, to be distributed from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration.

§ 2. Section 4325 of the insurance law is amended by adding a new subsection (p) to read as follows:

(p) (1) No corporation organized under this article shall by contract, written policy or written procedure allow or require an insurer-designated pharmacy to dispense a medication directly to a patient with the intention that the patient will transport the medication to a physician's office, hospital or clinic for administration.

(2) A corporation organized under this article may offer coverage for, but shall not require the use of a home infusion pharmacy to dispense sterile intravenous drugs ordered by physicians to patients in their homes or the use of an infusion site external to a patient's provider office or clinic.

(3) A corporation organized under this article, in order to require the distribution of patient-specific medication from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration, shall establish an agreement with the physician, hospital or clinic responsible for receiving and administering such medications to ensure proper receipt, transfer, handling, and storage of the medication prior to administration that includes, but is not limited to, the following provisions:

(A) provide at least ninety days' notice to providers and insureds prior to the implementation of such a requirement;

(B) have a patient-specific expedited exception process for cases in which a provider certifies that it is unsafe for a patient to receive medication from an insurer-designated pharmacy;

(C) provide same day delivery of medications;

(D) make available on-call access to a pharmacist or nurse twenty-four hours per day, seven days per week;

(E) utilize cold chain logistics or other means to ensure a drug remains at the appropriate temperature through all stages of supply and storage;

(F) provide a medication's pedigree to certify to the physician's office, hospital or clinic that the drug was handled appropriately through the supply chain;

(G) demonstrate expertise and reliability in risk evaluation and mitigation strategy to comply with United States food and drug administration reporting requirements;

(H) demonstrate the insurer-designated pharmacy is accredited by a national accreditation organization;

(I) demonstrate ability to deliver medications to a physician's office, hospital or clinic in a clinically appropriate dosage and in a ready-to-administer dosage form; and

(J) offer site neutral payment for such medications to the physician's office, hospital or clinic administering the medication, which payment shall include the costs for the providers to intake, store and dispose of such medications.

(4) No corporation organized under this article shall by contract, written policy or written procedure require (A) a medication requiring sterile compounding by the provider, or (B) a medication with a patient-specific dosage requirement to be based upon lab or test results on the day of the patient visit, to be distributed from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration.

§ 3. Section 4406-c of the public health law is amended by adding a new subdivision 13 to read as follows:

13. (a) No health care plan shall by contract or written policy or written procedure allow or require a plan-designated pharmacy to dispense a medication directly to a patient with the intention that the patient will transport the medication to a physician's office, hospital or clinic for administration.

(b) A health care plan may offer coverage for, but shall not require the use of a home infusion pharmacy to dispense sterile intravenous drugs ordered by physicians to patients in their homes or the use of an infusion site external to a patient's provider office or clinic.

(c) A health care plan, in order to require the distribution of patient-specific medication from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration, shall establish an agreement with the physician, hospital or clinic responsible for receiving and administering such medications to ensure proper receipt, transfer, handling, and storage of the medication prior to administration that includes, but is not limited to, the following provisions:

(i) provide at least ninety days' notice to providers and enrollees prior to the implementation of such a requirement;

(ii) have a patient-specific expedited exception process for cases in which a provider certifies that it is unsafe for a patient to receive medication from a plan-designated pharmacy;

(iii) provide same day delivery of medications;

(iv) make available on-call access to a pharmacist or nurse twentyfour hours per day, seven days per week;

(v) utilize cold chain logistics or other means to ensure a drug remains at the appropriate temperature through all stages of supply and storage;

(vi) provide a medication's pedigree to certify to the physician's office, hospital or clinic that the drug was handled appropriately through the supply chain;

(vii) demonstrate expertise and reliability in risk evaluation and mitigation strategy to comply with United States food and drug administration reporting requirements;

(viii) demonstrate the insurer-designated pharmacy is accredited by a national accreditation organization;

(ix) demonstrate ability to deliver medications to a physician's office, hospital or clinic in a clinically appropriate dosage and in a ready-to-administer dosage form; and

(x) offer site neutral payment for such medications to the physician's office, hospital or clinic administering the medication, which payment shall include the costs for the providers to intake, store and dispose of such medications.

(d) No health care plan shall by contract, written policy or written procedure require (i) a medication requiring sterile compounding by a provider, or (ii) a medication with a patient-specific dosage requirement to be based upon lab or test results on the day of the patient visit, to be distributed from a plan-designated pharmacy to a physician's office, hospital or clinic for administration.

§ 4. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law and the public health law, in relation to establishing patient safety and quality assurance measures regarding the distribution of patient-specific medication from an insurer-desig- nated pharmacy

Purpose or general idea of bill

The purpose of this legislation is to improve patient safety and quality assurance associated with health plan policies requiring the use of a designated pharmacy to dispense a specialty drug intended for adminis- tration by a clinician. These policies are commonly referred to as "white bagging" and "brown bagging."

Summary of specific provisions

This bill would amend §§ 3217-b and 4325 of the insurance law and 4406-c of the public health law to ensure quality assurance and patient safety regarding policies known as white and brown bagging of specialty drugs.

Read the full memo (793 words)

The bill would:Prohibit a health insurer from requiring the use of an insurer-designated pharmacy to dispense a drug directly to a patient with the intention that the patient will transport the medication to a physician's office, hospital or clinic for administration. This is type of policy is also known "brown bagging."

Authorize an insurer to offer coverage for, but not require, the use of a home infusion pharmacy. to dispense intravenous drugs that have been ordered by a physician for administration to a patient at a site other than the patient's provider site.

Prohibit an insurer from requiring the distribution of patient-specific medication from an insurer-designated pharmacy to a physician's office, hospital or clinic (known as "white bagging") unless the insurer has an agreement with the provider that is responsible for receiving and admin- istering the medication that includes specified notice, quality assur- ance and patient safety provisions.

Prohibit "white bagging" policies for medications requiring sterile compounding by a provider or medications with a patient-specific dosage requirement that is based on lab or test results on the day of the patient's visit.

Justification

Increasingly, health insurance plans have begun implementing policies that prohibit a healthcare provider from procuring and managing the handling of a drug used in patient care. Instead the insurer requires the use of an insurer-designated, third-party specialty pharmacy to dispense a specialty drug for administration by a clinician. These poli- cies are commonly referred to as "white bagging" and "brown bagging."

"Brown bagging" policies require a specialty drug to be dispensed by an insurer-designated pharmacy directly to a Patient, who then delivers the drug to a clinician for administration. This policy presents numerous chain of custody and patient safety concerns, which were recognized as problematic and as such, prohibited by the NYS Medicaid program in its August 2019 eMed guidance. The guidance states that this practice "caus- es concern regarding proper storage or handling, which can affect the drug efficacy. Brown bagging is not acceptable under NYS Medicaid." This bill would extend and apply this prohibition to all state-regulated insurance plans and policies.

"White bagging" policies also require the use of a third-party, insured-directed pharmacy to dispense a specialty drug. However, in this case, the drug is delivered directly to a hospital pharmacy or physi- cian's office, which then stores the drug until a clinician administers the drug to the patient. Since the provider no longer controls or owns the specialty drug, they cannot verify the source of the medications. Also since they are not responsible for coordinating the delivery and receipt of the drug they are unable to ensure that the drug was stored at the proper temperature prior to arrival at the hospital or clinic, or that the hospital or clinic is ready and able to receive and store products. Unexpected or surprise deliveries create significant, avoid- able challenges related to supply chain and storage capacity that could result in a violation of the individual hospital supply acquisition guidelines.

The NYS Medicaid program also recognizes this "white bagging" policy and deems it acceptable only under specific guidelines addressing concerns related to responsibility and timeliness of delivery of these drugs to the administering clinician. This bill would extend and expand these guidelines to all state-regulated insurance plans and policies to ensure that comprehensive patient protections and quality assurance measures are in place for all insureds, regardless of their health insurance plan.

The bill would also include additional "white bagging" protections to address patient care implications related to certain drug therapy treat- ments, such as oncology. The bill would prohibit "white bagging" for drugs that require a provider to make real-time medication adjustments based on necessary, same day lab and test results. This important patient-protection would prevent unnecessary delays in treatment, which could increase patient risk and adversely affect the patient's treat- ment.

Prior legislative history

S7252 - 2022

Fiscal implications

None to the state.

Effective date

This act shall take effect immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.